201 related articles for article (PubMed ID: 33832906)
1. Screening and molecular docking of selected phytochemicals against NS5B polymerase of hepatitis c virus.
Mustafa G; Majid M; Ghaffar A; Yameen M; Samad HA; Mahrosh HS
Pak J Pharm Sci; 2020 Sep; 33(5(Supplementary)):2317-2322. PubMed ID: 33832906
[TBL] [Abstract][Full Text] [Related]
2. Multiple e-pharmacophore modeling, 3D-QSAR, and high-throughput virtual screening of hepatitis C virus NS5B polymerase inhibitors.
Therese PJ; Manvar D; Kondepudi S; Battu MB; Sriram D; Basu A; Yogeeswari P; Kaushik-Basu N
J Chem Inf Model; 2014 Feb; 54(2):539-52. PubMed ID: 24460140
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of Taraxacum officinale against HCV NS5B polymerase: In-vitro and In silico study.
Rehman S; Ijaz B; Fatima N; Muhammad SA; Riazuddin S
Biomed Pharmacother; 2016 Oct; 83():881-891. PubMed ID: 27513212
[TBL] [Abstract][Full Text] [Related]
4. Molecular Docking and Pharmacoinformatics Studies Reveal Potential Phytochemicals Against HCV NS5B Polymerase.
Khalid H; Ashfaq UA
Comb Chem High Throughput Screen; 2022; 25(2):335-346. PubMed ID: 33371844
[TBL] [Abstract][Full Text] [Related]
5. Combination of pharmacophore hypothesis and molecular docking to identify novel inhibitors of HCV NS5B polymerase.
Harikishore A; Li E; Lee JJ; Cho NJ; Yoon HS
Mol Divers; 2015 Aug; 19(3):529-39. PubMed ID: 25862642
[TBL] [Abstract][Full Text] [Related]
6. Novel Guanosine Derivatives as Anti-HCV NS5b Polymerase: A QSAR and Molecular Docking Study.
Elfiky AA
Med Chem; 2019; 15(2):130-137. PubMed ID: 30324891
[TBL] [Abstract][Full Text] [Related]
7. Screening of hepatitis C NS5B polymerase inhibitors containing benzothiadiazine core: a steered molecular dynamics.
Nutho B; Meeprasert A; Chulapa M; Kungwan N; Rungrotmongkol T
J Biomol Struct Dyn; 2017 Jun; 35(8):1743-1757. PubMed ID: 27236925
[TBL] [Abstract][Full Text] [Related]
8. Searching for anthranilic acid-based thumb pocket 2 HCV NS5B polymerase inhibitors through a combination of molecular docking, 3D-QSAR and virtual screening.
Vrontaki E; Melagraki G; Mavromoustakos T; Afantitis A
J Enzyme Inhib Med Chem; 2016; 31(1):38-52. PubMed ID: 26060939
[TBL] [Abstract][Full Text] [Related]
9. Structural insights into NS5B protein of novel equine hepaciviruses and pegiviruses complexed with polymerase inhibitors.
de Albuquerque PPLF; Santos LHS; Antunes D; Caffarena ER; Figueiredo AS
Virus Res; 2020 Mar; 278():197867. PubMed ID: 31972246
[TBL] [Abstract][Full Text] [Related]
10. Combined 3D-QSAR, molecular docking, molecular dynamics simulation, and binding free energy calculation studies on the 5-hydroxy-2H-pyridazin-3-one derivatives as HCV NS5B polymerase inhibitors.
Yu H; Fang Y; Lu X; Liu Y; Zhang H
Chem Biol Drug Des; 2014 Jan; 83(1):89-105. PubMed ID: 23941500
[TBL] [Abstract][Full Text] [Related]
11. Combining 3-D quantitative structure-activity relationship with ligand based and structure based alignment procedures for in silico screening of new hepatitis C virus NS5B polymerase inhibitors.
Musmuca I; Caroli A; Mai A; Kaushik-Basu N; Arora P; Ragno R
J Chem Inf Model; 2010 Apr; 50(4):662-76. PubMed ID: 20225870
[TBL] [Abstract][Full Text] [Related]
12. Rational Drug Discovery of HCV Helicase Inhibitor: Improved Docking Accuracy with Multiple Seeding in AutoDock Vina and In Situ Minimization.
Lim SK; Othman R; Yusof R; Heh CH
Curr Comput Aided Drug Des; 2017; 13(2):160-169. PubMed ID: 27903217
[TBL] [Abstract][Full Text] [Related]
13. Probing the "fingers" domain binding pocket of Hepatitis C virus NS5B RdRp and D559G resistance mutation via molecular docking, molecular dynamics simulation and binding free energy calculations.
Manjula S; Sivanandam M; Kumaradhas P
J Biomol Struct Dyn; 2019 Jun; 37(9):2440-2456. PubMed ID: 30047829
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C Virus NS3/4A Inhibition and Host Immunomodulation by Tannins from
Patil VS; Harish DR; Vetrivel U; Roy S; Deshpande SH; Hegde HV
Molecules; 2022 Feb; 27(3):. PubMed ID: 35164341
[No Abstract] [Full Text] [Related]
15. Multiple virtual screening approaches for finding new hepatitis C virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitors.
Elhefnawi M; ElGamacy M; Fares M
BMC Bioinformatics; 2012; 13 Suppl 17(Suppl 17):S5. PubMed ID: 23282180
[TBL] [Abstract][Full Text] [Related]
16. Computational screening of medicinal plant phytochemicals to discover potent pan-serotype inhibitors against dengue virus.
Tahir Ul Qamar M; Maryam A; Muneer I; Xing F; Ashfaq UA; Khan FA; Anwar F; Geesi MH; Khalid RR; Rauf SA; Siddiqi AR
Sci Rep; 2019 Feb; 9(1):1433. PubMed ID: 30723263
[TBL] [Abstract][Full Text] [Related]
17. 2-(3-Thienyl)-5,6-dihydroxypyrimidine-4-carboxylic acids as inhibitors of HCV NS5B RdRp.
Pacini B; Avolio S; Ercolani C; Koch U; Migliaccio G; Narjes F; Pacini L; Tomei L; Harper S
Bioorg Med Chem Lett; 2009 Nov; 19(21):6245-9. PubMed ID: 19800789
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Novel Hepatitis C Virus NS5B Polymerase Inhibitors by Combining Random Forest, Multiple e-Pharmacophore Modeling and Docking.
Wei Y; Li J; Qing J; Huang M; Wu M; Gao F; Li D; Hong Z; Kong L; Huang W; Lin J
PLoS One; 2016; 11(2):e0148181. PubMed ID: 26845440
[TBL] [Abstract][Full Text] [Related]
19. Interference of HCV replication by cell penetrable human monoclonal scFv specific to NS5B polymerase.
Thueng-in K; Thanongsaksrikul J; Jittavisutthikul S; Seesuay W; Chulanetra M; Sakolvaree Y; Srimanote P; Chaicumpa W
MAbs; 2014; 6(5):1327-39. PubMed ID: 25517317
[TBL] [Abstract][Full Text] [Related]
20. Novel 4-thiazolidinones as non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA polymerase.
Çakir G; Küçükgüzel İ; Guhamazumder R; Tatar E; Manvar D; Basu A; Patel BA; Zia J; Talele TT; Kaushik-Basu N
Arch Pharm (Weinheim); 2015 Jan; 348(1):10-22. PubMed ID: 25449674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]